You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九芝堂(000989.SZ):參股公司研發新藥Volagidemab(即REMD-477項目)發佈Ⅱ期臨牀試驗結果
格隆匯 06-29 16:53

格隆匯6月29日丨九芝堂(000989.SZ)公佈,近日,公司收到參股公司北京科信美德生物醫藥科技有限公司(“科信美德”)的通知,其與母公司美國瑞美德生物醫藥公司(REMD Biotherapeutics Inc)在美國糖尿病協會(ADA)第81屆科學會議(ADA2021)上首次發佈研發新藥Volagidemab(即REMD-477項目)治療1型糖尿病患者的Ⅱ期臨牀試驗結果。

該次Ⅱ期臨牀試驗的試驗結果:Volagidemab能夠降低糖化血紅蛋白和每日胰島素使用量,並且具有臨牀意義的統計學意義,且Volagidemab治療並未觀察到低血糖事件增加。研究結果為推進Volagidemab的臨牀試驗工作提供了有力依據。

據悉,Volagidemab是一個胰高血糖素受體的完全競爭性拮抗型全人源抗體,於2013年獲得安進公司(Amgen)的全球排他性授權,目前正在用於治療1型糖尿病的臨牀研究以及用於治療其他代謝性疾病的臨牀前研究。該藥物如開發成功,將證明胰高血糖素通路的過分活化是糖尿病的主要病因之一,該藥物將是全球第一個通過阻斷胰高血糖素受體通路治療糖尿病的全新抗體藥物。Volagidemab在美國已經完成了1型糖尿病的Ⅱ期臨牀試驗,後續還需進行Ⅲ期臨牀試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account